Pang-Dian Fan

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 5

Top Topics

Epidermal Growth Factor Receptor

Tyrosine Kinase

Top Venues

Future oncology (London, England)

JCO precision oncology

Proceedings of the National Academy of Sciences of the United States of America

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Helena A Yu, James Chih-Hsin Yang, Hidetoshi Hayashi, Yasushi Goto, Enriqueta Felip, Martin Reck, Michele Vigliotti, Qian Dong, Frédérique Cantero, Pang-Dian Fan, Masayuki Kanai, David W Sternberg, Pasi A Janne
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR -mutated NSCLC. Future oncology (London, England) (2023)
Helena Alexandra Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip Font, James Chih-Hsin Yang, Martin Reck, Kiyotaka Yoh, Se-Hoon Lee, Luis G Paz-Ares, Benjamin Besse, Paolo Bironzo, Dong Wan Kim, Melissa Lynne Johnson, Yi-Long Wu, Thomas John, Steven Kao, Toshiyuki Kozuki, Erminia Massarelli, Jyoti D Patel, Egbert F Smit, Karen L Reckamp, Qian Dong, Pomy Shrestha, Pang-Dian Fan, Parul Patel, Andrea Sporchia, David W Sternberg, Dalila Sellami, Pasi A Janne
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Tony S K Mok, Pasi A Janne, Makoto Nishio, Silvia Novello, Martin Reck, Conor E Steuer, Yi-Long Wu, Ronan Fougeray, Pang-Dian Fan, Jie Meng, David W Sternberg, Stephen Esker, Helena Alexandra Yu
HERTHENA-Lung02: phase III study of patritumab deruxtecan in advanced EGFR -mutated NSCLC after a third-generation EGFR TKI. Future oncology (London, England) (2023)
Hiroki Sato, Daisuke Kubota, Huan Qiao, Achim Jungbluth, Natasha Rekhtman, Adam J Schoenfeld, Helena Alexandra Yu, Gregory J Riely, Shinichi Toyooka, Christine M Lovly, Paul K Paik, Marc Ladanyi, Pang-Dian Fan
SRC Family Kinase Inhibition Targets YES1 and YAP1 as Primary Drivers of Lung Cancer and as Mediators of Acquired Resistance to ALK and Epidermal Growth Factor Receptor Inhibitors. JCO precision oncology 6 (2022)
Pang-Dian Fan, Giuseppe Narzisi, Anitha D Jayaprakash, Elisa Venturini, Nicolas Robine, Peter Smibert, Soren Germer, Helena A Yu, Emmet J Jordan, Paul K Paik, Yelena Y Janjigian, Jamie E Chaft, Lu Wang, Achim A Jungbluth, Sumit Middha, Lee Spraggon, Huan Qiao, Christine M Lovly, Mark G Kris, Gregory J Riely, Katerina Politi, Harold Varmus, Marc Ladanyi
YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics. Proceedings of the National Academy of Sciences of the United States of America 115 (26) (2018)